Pioneering Technique Offers Accurate Prognosis for Patients with CLL

According to researchers from Cardiff University's School of Medicine, prognosis in patients with chronic lymphocytic leukemia (CLL) can be accurately determined by measuring the length and function telomeres.

So what are telomeres?

Telomeres are repeating sections of DNA that are found at the ends of chromosomes.

Applying new and pioneering techniques to determine if the telomeres were working or not in cells from patients with CLL, they found that patients with short dysfunctional telomeres had much poorer clinical outcome compared to those with long and functional telomeres.

"For the first time, confident predictions of clinical outcome can be made for individual CLL patients at diagnosis based on accurate analysis of the length of telomeres in cancer cells," said Professor Chris Pepper, who led the current research. "This should prove enormously valuable to doctors, patients and their families and there is no reason why there should not be widespread implementation of this powerful prognostic tool in the near future."

"The accuracy of this test in predicting how a person's disease will develop is unprecedented and, if confirmed in clinical trials, would help doctors decide on the best treatment courses for individual CLL patients," added Dr Matt Kaiser, Head of Research at Leukaemia & Lymphoma Research, who helped fund the study. "Telomeres are known to play a part in the progress of other forms of cancer, so this type of testing could have far-reaching benefits."

While the results offered here need to be confirmed in larger trials, they certainly offer some hope that CLL prognosis can be determined before treatment begins so that that treatment can be tailored for the individual patient and therefore be as effective as possible.

On top of that, there is a psychological benefit to receiving an accurate and reliable prognosis from one's doctors for the patient, allowing them to avoid the uncertainty that normally attends any attempt at prognosis by most physicians.

The researchers' results were reported online in the British Journal of Haematology.

Source: MNT

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap